Peeters K C M J, van de Velde C J H, Leer J W H, Martijn H, Junggeburt J M C, Kranenbarg E Klein, Steup W H, Wiggers T, Rutten H J, Marijnen C A M
Department of Surgery, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands.
J Clin Oncol. 2005 Sep 1;23(25):6199-206. doi: 10.1200/JCO.2005.14.779.
Preoperative short-term radiotherapy improves local control in patients treated with total mesorectal excision (TME). This study was performed to assess the presence and magnitude of long-term side effects of preoperative 5 x 5 Gy radiotherapy and TME. Also, hospital treatment was recorded for diseases possibly related to late side effects of rectal cancer treatment.
Long-term morbidity was assessed in patients from the prospective randomized TME trial, which investigated the efficacy of 5 x 5 Gy before TME surgery for mobile rectal cancer. Dutch patients without recurrent disease were sent a questionnaire.
Results were obtained from 597 patients, with a median follow-up of 5.1 years. Stoma function, urinary function, and hospital treatment rates did not differ significantly between the treatment arms. However, irradiated patients, compared with nonirradiated patients, reported increased rates of fecal incontinence (62% v 38%, respectively; P < .001), pad wearing as a result of incontinence (56% v 33%, respectively; P < .001), anal blood loss (11% v 3%, respectively; P = .004), and mucus loss (27% v 15%, respectively; P = .005). Satisfaction with bowel function was significantly lower and the impact of bowel dysfunction on daily activities was greater in irradiated patients compared with patients who underwent TME alone.
Although preoperative short-term radiotherapy for rectal cancer results in increased local control, there is more long-term bowel dysfunction in irradiated patients than in patients who undergo TME alone. Rectal cancer patients should be informed on late morbidity of both radiotherapy and TME. Future strategies should be aimed at selecting patients for radiotherapy who are at high risk for local failure.
术前短期放疗可改善接受全直肠系膜切除术(TME)患者的局部控制。本研究旨在评估术前5×5 Gy放疗及TME的长期副作用的存在情况及严重程度。此外,还记录了可能与直肠癌治疗晚期副作用相关疾病的住院治疗情况。
对前瞻性随机TME试验中的患者进行长期发病率评估,该试验研究了TME手术前5×5 Gy放疗对可移动直肠癌的疗效。向无复发病症的荷兰患者发送问卷。
共获得597例患者的结果,中位随访时间为5.1年。各治疗组之间的造口功能、泌尿功能及住院治疗率无显著差异。然而,与未接受放疗的患者相比,接受放疗的患者报告粪便失禁发生率增加(分别为62%对38%;P<.001)、因失禁使用护垫的发生率增加(分别为56%对33%;P<.001)、肛门失血增加(分别为11%对3%;P=.004)以及黏液流失增加(分别为27%对15%;P=.005)。与仅接受TME手术的患者相比,接受放疗的患者对肠道功能的满意度显著较低,且肠道功能障碍对日常活动的影响更大。
尽管直肠癌术前短期放疗可提高局部控制率,但接受放疗的患者比仅接受TME手术的患者存在更多的长期肠道功能障碍。应告知直肠癌患者放疗及TME的晚期发病率。未来策略应旨在选择局部失败风险高的患者进行放疗。